Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02587351 · ClinicalTrials.gov registry record · Phase 3
Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease
A Phase 3 study, sponsored by University of Minnesota.
- Terminated
- Registry status
- Phase 3
- Development phase
- 532
- Enrollment target
NCT02587351 is a Phase 3 study that was terminated before completion, run by University of Minnesota. The registered enrollment target is 532 participants.
The verdict
NCT02587351, a Phase 3 study, was terminated before completion, sponsored by University of Minnesota.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 532 participants
- Enrollment target
Study Summary
This is a multicenter, prospective, randomized, double-blind, placebo-controlled trial that will enroll 1028 patients with at least moderately severe COPD over a three year period and follow them at regular intervals for one year. The primary endpoint is time to first acute exacerbation. Secondary endpoints include rates and severity of COPD exacerbations, cardiovascular events, all-cause mortality, lung function, dyspnea, quality of life and metoprolol-related side effects.
Interventions
- OTHER Placebo
- DRUG Metoprolol succinate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 532 participants |
| Start Date | 2016-05-01 |
| Est. Completion | 2019-12-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02587351
The ClinicalTrials.gov registry entry for NCT02587351 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 532 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02587351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02587351 about?
NCT02587351 is a clinical study titled "Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease". This is a multicenter, prospective, randomized, double-blind, placebo-controlled trial that will enroll 1028 patients with at least moderately severe COPD over a three year period and follow them at regular intervals for one year. The primary endpoint is time to first acute exacerbation. Secondary e...
What is the current status of trial NCT02587351?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 532 participants. The study started on 2016-05-01. Estimated completion is 2019-12-01.
What interventions are being tested in trial NCT02587351?
The interventions under investigation include: Placebo (OTHER), Metoprolol succinate (DRUG).
Who is sponsoring clinical trial NCT02587351?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.